Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Claudiani

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Research and Practice in Thrombosis and Haemostasis|July 25, 2025
Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome-insights from a UK centerGiulia Simini, Andrew Innes, Saravanan Vinayagam, et al.
British Journal of Haematology|January 8, 2022
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Katherine M Dominy, Simone Claudiani, Matthew O'Hare, et al.
Haematologica|May 13, 2017
E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapySimone Claudiani, Jane F Apperley, Robert Peter Gale, et al.
Bone Marrow Transplantation|April 4, 2023
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemiaFiona Fernando, Andrew J Innes, Simone Claudiani, et al.
Leukemia & Lymphoma|April 23, 2024
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemiaGeorge Nesr, Simone Claudiani, Dragana Milojkovic, et al.
Leukemia|February 29, 2024
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistanceSimone Claudiani, Farhan Chughtai, Afzal Khan, et al.
Journal of Clinical Pathology|April 21, 2019
T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented reportBrian Hanley, George Nesr, Eva Yebra-Fernandez, et al.
BMC Medical Genomics|July 26, 2023
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertionsPhilippa C May, Alistair G Reid, Mark E Robinson, et al.
Haematologica|March 30, 2019
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemiaSimone Claudiani, Aoife Gatenby, Richard Szydlo, et al.
British Journal of Haematology|December 19, 2021
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitorsSimone Claudiani, Jane F Apperley, Eleanor L Parker, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Research and Practice in Thrombosis and Haemostasis|July 25, 2025
Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome-insights from a UK centerGiulia Simini, Andrew Innes, Saravanan Vinayagam, et al.
British Journal of Haematology|January 8, 2022
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Katherine M Dominy, Simone Claudiani, Matthew O'Hare, et al.
Haematologica|May 13, 2017
E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapySimone Claudiani, Jane F Apperley, Robert Peter Gale, et al.
Bone Marrow Transplantation|April 4, 2023
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemiaFiona Fernando, Andrew J Innes, Simone Claudiani, et al.
Leukemia & Lymphoma|April 23, 2024
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemiaGeorge Nesr, Simone Claudiani, Dragana Milojkovic, et al.
Leukemia|February 29, 2024
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistanceSimone Claudiani, Farhan Chughtai, Afzal Khan, et al.
Journal of Clinical Pathology|April 21, 2019
T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented reportBrian Hanley, George Nesr, Eva Yebra-Fernandez, et al.
BMC Medical Genomics|July 26, 2023
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertionsPhilippa C May, Alistair G Reid, Mark E Robinson, et al.
Haematologica|March 30, 2019
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemiaSimone Claudiani, Aoife Gatenby, Richard Szydlo, et al.
British Journal of Haematology|December 19, 2021
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitorsSimone Claudiani, Jane F Apperley, Eleanor L Parker, et al.
Pageof 4